Evolus, Inc. (EOLS): R&D Expense
$9.58M
Year ended 2025-12-31
$9.66M
Trailing 12 months to 2026-06-30
+26.4%
3-year compound annual growth
+40.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.58M | +4.4% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $9.17M | +39.9% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $6.56M | +38.3% | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | $4.74M | +129.7% | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | $2.06M | +19.9% | 2023-03-08, From 2021-01-01 |
| 2020-12-31 | $1.72M | -56.7% | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | $3.97M | -38.8% | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $6.49M | -3.0% | 2020-02-25, From 2018-01-01 |
| 2017-12-31 | $6.69M | n/a | 2019-03-20, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 2025-12-31 | $9.58M | +4.4% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $95.14M | -14.6% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $31.16M | +21.9% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $19.33M | +390.4% |
| Harrow, Inc. (HROW) | 2025-12-31 | $20.94M | +71.2% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $81.18M | +278.9% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $285.20M | -18.1% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $173.14M | -14.2% |
| MannKind Corp (MNKD) | 2025-12-31 | $66.35M | +44.6% |
Compare EOLS, IRWD, XERS, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗